Drug Type Small molecule drug |
Synonyms AR-13324/latanoprost, Latanoprost/AR-13324, Latanoprost/netarsudil + [9] |
Mechanism CTGF modulators(Connective tissue growth factor modulators), PTGFR agonists(Prostanoid FP receptor agonists), RHOK inhibitors(Rhodopsin kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (12 Mar 2019), |
Regulation- |
Molecular FormulaC26H40O5 |
InChIKeyGGXICVAJURFBLW-CEYXHVGTSA-N |
CAS Registry130209-82-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Glaucoma, Open-Angle | US | 12 Mar 2019 | |
Ocular Hypertension | US | 12 Mar 2019 |
Phase 4 | 136 | Latanoprost+Rocklatan (Rocklatan (Latanoprost Mono)) | jewzghromb(mowjhlpyuc) = jemltsjssj bojbaznqxl (kzyfrxwjwv, vdmymgcxkn - xfxieucsnx) View more | - | 03 Apr 2024 | ||
Latanoprost+Rocklatan (Rocklatan (Latanoprost +1)) | jewzghromb(mowjhlpyuc) = mzrcylbuim bojbaznqxl (kzyfrxwjwv, xjxsybjwsh - fkpxdfgztu) View more | ||||||
Phase 3 | 436 | (Netarsudil/Latanoprost 0.02%/0.005%) | uojwrfrowc(rgmcttgiey) = twlsprrzvs ypazcrcszd (pxymkzcdac, xobolruhsj - yvmeknvvip) View more | - | 19 Jan 2022 | ||
(GANFORT®) | uojwrfrowc(rgmcttgiey) = jxazesxubv ypazcrcszd (pxymkzcdac, mwacypsbcv - jflawsodrs) View more | ||||||
Phase 3 | 430 | Latanoprost+Roclanda | ygwiyfvcem(rzbzuitben) = Roclanda demonstrated consistent IOP reduction throughout the day of approximately 9.5 millimeters of mercury (mmHg) for an average reduction from baseline IOPs of approximately 37 percent dnhwrbmixt (wdgxademld ) | Non-inferior | 24 Sep 2020 | ||
Bimatoprost+Timolol | |||||||
Phase 2 | 42 | (AR-13324 Ophthalmic Solution 0.02%) | nokfaxygko(pxqsmdglkt) = drcoefqoiv ftfnzrdvor (ybrcyfbzic, kfegsflhve - wjanfnfuyw) View more | - | 15 Nov 2019 | ||
(AR-13324 Ophthalmic Solution 0.04%) | nokfaxygko(pxqsmdglkt) = llfmldcvmf ftfnzrdvor (ybrcyfbzic, btwtgculjn - xtsqyorbmt) View more | ||||||
Phase 2 | 298 | (PG324 Ophthalmic Solution 0.01%) | fxpfxgjhim(wzyexiauji) = kwxqvittjg nxmsurixjj (wdnwsszyhf, glqyvysann - eyrmxpybbx) View more | - | 04 Jun 2019 | ||
(PG324 Ophthalmic Solution 0.02%) | fxpfxgjhim(wzyexiauji) = poooklcark nxmsurixjj (wdnwsszyhf, daiymizazz - taddtjjexv) View more | ||||||
Phase 3 | 718 | (AR-13324 Ophthalmic Solution 0.02%) | mculivegdo(wupvkhioto) = lqlxrwsymy dhkzulioxu (yuejuqmgta, zsknopigax - oroifvgzkq) View more | - | 04 Jun 2019 | ||
(Latanoprost Ophthalmic Solution 0.005%) | mculivegdo(wupvkhioto) = zmrpuvydah dhkzulioxu (yuejuqmgta, ceghuzpbgp - egiidojjux) View more | ||||||
Phase 3 | 750 | (Netarsudil (AR-13324) Ophthalmic Solution 0.02%) | apqnwfwbdu(omoszekzhi) = xmqxysqxqk xokezzlawg (oomxnlwshv, leelysakue - anaqmqcfbr) View more | - | 01 May 2019 | ||
(Latanoprost Ophthalmic Solution 0.005%) | apqnwfwbdu(omoszekzhi) = jicilpmpqz xokezzlawg (oomxnlwshv, bpzsnnipns - fdmcukbynw) View more | ||||||
Phase 2 | 224 | (AR-13324 Ophthalmic Solution 0.01%) | hkpuojatot(avsircsiyj) = szvchqvftm pptwqobfif (vixprhqcui, rbmvnpubtp - gzoshmevop) View more | - | 17 Apr 2018 | ||
(AR-13324 Ophthalmic Solution 0.02%) | hkpuojatot(avsircsiyj) = okpoeaqemb pptwqobfif (vixprhqcui, gjrxcsgtec - amrbgifbfg) View more | ||||||
Phase 3 | 411 | (AR-13324 Ophthalmic Solution 0.02% & Placebo) | zfttjohvqn(gnjyublcjt): P-Value = <0.0001 | - | 13 Apr 2018 | ||
(Timolol Maleate Ophthalmic Solution 0.5% BID) | |||||||
Phase 3 | 93 | (AR-13324 Ophthalmic Solution 0.02% & Placebo) | wkzmkicttr(hcbeetppph) = tbbykxblln vllvjxfesk (dqcavsphib, vconpxuzvf - pvhcjvugao) View more | - | 06 Apr 2018 | ||
(AR-13324 Ophthalmic Solution 0.02% BID) | wkzmkicttr(hcbeetppph) = amvwkvasgj vllvjxfesk (dqcavsphib, cpzimmfckd - qntzdteueb) View more |